As we look back on the past year, we are proud of the progress and impact reflected in these highlights. None of this would have been possible without the close collaboration, trust, and pioneering spirit of the researchers at Utrecht
Nieuwe innovaties in de markt zetten; dat is de uitdaging waar Utrecht Holdings (Universiteit Utrecht Holding en UMC Utrecht Holding) samen met onderzoekers van UMC Utrecht en Universiteit Utrecht elke dag voor staan. Met als doel een zo groot mogelijke
Utrecht Holdings is proud to offer a patent-pending CAR-T cell therapy platform developed by researchers at UMC Utrecht.
The winner of the Venture Challenge was announced today at the Dutch Biotech Event. The proud winner of the 2025 Spring edition is NeuroNova Tx! Their groundbreaking stem cell research stimulates brain repair in newborn babies who suffered from brain
As coordinator of the research project Neoliver, Bart Spee leads the international consortium of twelve research institutions and companies. Below is an article in Trouw about the development of the Neoliver.
Ready to turn your Science into Impact?
Together with the Faculty of Impact, we have organized an information session at our office. Do you have any questions or are you interested? Come by to our office (Bestuursgebouw 0.43) and
We can look back on another great, innovative year.
We thank all researchers from the UU and the UMCU.
Utrecht Holdings and BigCircle Ventures have joined forces to commercialise the catalytic ball milling technology, a breakthrough developed in the lab of Assistant Professor Ina Vollmer at Utrecht University.
UMC Utrecht spin-off company TigaTx, Inc. recently announced that the Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $33.5 million in funding. Separately, TigaTx was awarded a $2 million grant from the National Cancer Institute (NCI), part